Ranbaxy Labs - Q1CY12 Result update/ Estimate change - CentrumEquity BullsRLL reported 71%YoY growth in revenues due to FTF opportunities of generic Lipitor and Caduet in the US market.

Business TodayLipitor delivers impressive margins for RanbaxyHindu Business LineRanbaxy Laboratories' sales growth and high profit margins were helped mainly by sales of Lipitor and Caduet on an exclusive basis in the US.

Moneycontrol.

Business LineRanbaxy: Positives priced inBusiness Standard (blog)Sales in the US surged a huge 159 per cent to $410 million in the March quarter, of which Lipitor (a cholesterol lowering drug) and Caduet (a drug prescribed to treat conditions that affect the heart and blood vessels) contributed around $316 million.

Wall Street JournalRanbaxy's Net Profit SoarsWall Street JournalThe introduction of the much-awaited Lipitor generic in November, followed by authorized sales of a generic version of Pfizer's Caduet blood-pressure pill, contributed in a big way to Ranbaxy's sales and earnings.